Patient Information

CSL Behring UK Ltd is committed to improving the quality of life for patients with rare diseases, including immune deficiency disorders, haemophilia and von Willebrand disease.

Our therapies are also used for congenital fibrinogen deficiency, rapid warfarin reversal and to prevent haemolytic disease of the newborn.

Coagulation
CSL Behring UK Ltd provides a range of therapies to treat coagulation disorders such as haemophilia, von Willebrand disease and congenital fibrinogen deficiency.

CSL Behring UK Ltd also manufactures a product for rapid warfarin reversal. Warfarin is a medicine which thins the blood and is used to reduce the risk of blood clots. When a person on warfarin experiences a serious bleeding episode, it may be necessary to reverse the effects of warfarin to stop the bleeding.

Haemophilia is a problem with the blood in which there is not enough of one of the clotting factors needed for blood clots to form.

People with von Willebrand disease also have a problem with one of the clotting factors in the blood; this particular clotting factor is known as von Willebrand factor.

Congenital fibrinogen deficiency is where an essential protein required for a blood clot to form is either missing, significantly reduced or dysfunctional.

Immunology
In the area of immunology, CSL Behring UK Ltd provides a range of therapies for immune deficiency disorders, hereditary angioedema and to prevent haemolytic disease of the newborn.

Immune deficiency disorders – in general, immunodeficiency means that one or more components of the immune system are either absent or are not working properly.

Haemolytic disease of the newborn is caused when the blood group of the mother and baby are not compatible.

UK/CORP/11-0061ah Date of preparation: Dec 2011